Aethlon Medical reported financial results for fiscal year 2024, with a net loss of $12.2 million compared to $12.0 million in FY2023. The company ended the year with $5.4 million in cash, down from $14.5 million, while operating expenses increased slightly to $12.6 million from $12.5 million year-over-year.The company made significant progress in its clinical development programs, receiving FDA approval in April 2024 to manufacture Hemopurifiers at its San Diego facility. Aethlon completed an in vitro binding study showing positive results for its Hemopurifier in removing extracellular vesicles from plasma, supporting planned Phase 1 trials in solid tumor patients. In June 2024, the company received Ethics Committee approval from Royal Adelaide Hospital for its Phase 1 oncology trial.Post fiscal year-end, Aethlon strengthened its financial position by raising $4.7 million in gross proceeds through a public offering in May 2024, followed by warrant exercises generating an additional $1.8 million in June. The company continues to advance its clinical programs while implementing cost reduction measures, though management notes substantial doubt about having sufficient cash for 12 months of operations.

Aethlon Medical reported financial results for fiscal year 2024, with a net loss of $12.2 million compared to $12.0 million in FY2023. The company ended the year with $5.4 million in cash, down from $14.5 million, while operating expenses increased slightly to $12.6 million from $12.5 million year-over-year.The company made significant progress in its clinical development programs, receiving FDA approval in April 2024 to manufacture Hemopurifiers at its San Diego facility. Aethlon completed an in vitro binding study showing positive results for its Hemopurifier in removing extracellular vesicles from plasma, supporting planned Phase 1 trials in solid tumor patients. In June 2024, the company received Ethics Committee approval from Royal Adelaide Hospital for its Phase 1 oncology trial.Post fiscal year-end, Aethlon strengthened its financial position by raising $4.7 million in gross proceeds through a public offering in May 2024, followed by warrant exercises generating an additional $1.8 million in June. The company continues to advance its clinical programs while implementing cost reduction measures, though management notes substantial doubt about having sufficient cash for 12 months of operations.